IAOe?IIAEUeIA AEAAeAI?ss IAOE OE?A?IE

?INOEOOO O?C?IEIA?? ?I. I.I. AIAIIIEUeOess

Nieieaiei Aaaeei Eaii?aeiae/

OAeE 612.017.1:612.112.94:612.014.482:612.275

AENI?AN?ss O -EE?OEIIEO IIAA?OIAAEO IA?EA??A E?IOIOeEOAIE O I?AEOE*II
CAeI?IAEO IN?A, UI CACIAEE AIEEAO OAEOI??A AAA??? IA *AAN

03.00.13 — O?c?ieia?y ethaeeie ? oaa?ei

AAOI?AOA?AO

aeena?oaoe?? ia caeiaoooy iaoeiaiai nooiaiy

eaiaeeaeaoa a?ieia?/ieo iaoe

Ee?a-1998 ?.

Aeena?oaoe??th ? ?oeiien.

?iaioa aeeiiaia o *a?eanueeiio aea?aeaaiiio oi?aa?neoao? ?i. Aiaaeaia
Oiaeueieoeueeiai.

Iaoeiaee ea??aiee: aeieoi? a?ieia?/ieo iaoe, i?ioani?,

Aa?aa Ieaia A?eoi??aia

*a?eanueeee ?inoeooo oi?aae?iiy a?cianii

caa. eaoaae?ith iaiaaeaeiaioo iaaee/iiai ianeoaiaoaaiiy

Io?oe?ei? iiiiaioe: aeieoi? a?ieia?/ieo iaoe

Aeaen??aa ??eia Ieeiea?aia

?inoeooo o?c?ieia?? ?i. I.I. Aiaiiieueoey

caa a?aeae?eii ?ioiieia?? ? oeeoioiene/ieo ne?iaaoie

aeieoi? a?ieia?/ieo iaoe

I?i/aiei AEaiia Ieeiea?aia

?inoeooo ee?i?/ii? ?aae?ieia?? AII Oe?a?ie

ea??aiee eaai?aoi??? oeaieiiiai oeo?oaaiiy ? oeeoio?i??

I?ia?aeia onoaiiaa: ?inoeooo aa?iioieia?? AII Oe?a?ie, i. Ee?a

Caoeno a?aeaoaeaoueny “2” aa?aciy 1999 ?ieo i 14-00 aiaeei? ia
can?aeaii? niaoe?aeueii? a/aii? ?aaee Ae 26. 198. 01 i?e ?inoeooo?
o?c?ieia?? ?i. I.I.Aiaiiieueoey IAI Oe?a?ie (252024 i.Ee?a, aoe.
Aiaiiieueoey, 4).

C aeena?oaoe??th iiaeia iciaeiieoeny o a?ae?ioaoe? ?inoeoooo o?c?ieia??
?i. I.I.Aiaiiieueoey IAI Oe?a?ie ca aae?anith: 252024 i.Ee?a, aoe.
Aiaiiieueoey, 4.

Aaoi?aoa?ao ?ic?neaiee “1” ethoiai 1999 ?.

A/aiee nae?aoa?

niaoe?ae?ciaaii? a/aii? ?aaee

aeieoi? a?ieia?/ieo iaoe C.I.Ni?ie?ia-Ia??ia

CAAAEUeIA OA?AEOA?ENOEEA ?IAIOE

Aeooaeuei?noue i?iaeaie. Aiane?aeie aeniei? aeeiai?/iino? oa neeaaeii?
nenoaie ?aaoeyoe??, ia?aiao?e iniiaieo iieaciee?a ?ioiii? nenoaie i?ae
aieeaii ciai?oi?o /e aioo??oi?o noeioe?a iiaeooue a iaaieo iaaeao
ci?ithaaoenue (Sheehan K.C.F. et al., 1987; Altman A. et al.,1990; Claus
C. et al., 1994; Kuvano K. et al., 1994; Iiaeeiaa A.I., 1995; Vanr?jn J.
et al., 1996; N?lsson M. et al., 1996). I?e iineeai?e /e eiia?iiaai?e
ae?? aeno?aiaeueieo oaeoi??a ciai?oiueiai na?aaeiaeua iiaeeeaa
aeieeiaiiy aoaeoo “ia?aiai?oae” ?ioiiiai eiiiiiaioo aiiainoaco, ui
i?aeaeuo? ?ecee caoai?thaaiue na?aae ianaeaiiy aeieia?/ii-caa?oaeiaieo
?aa?ii?a (O?ieia A.I. e ae?., 1998). Cia/ia /anoeia iaoeaioe?a Oe?a?ie
caciaea aieeao oaeoi??a aaa??? ia *AAN. Iaea?eueo /ooeeaeie aei ae??
?ii?coth/i? ?aae?aoe?? no?oeoo?aie ?ioiii? nenoaie ? iiaa?oiaa? aioeaaie
e?ioioeeo?a (Etha/aiei I.I. e ae?., 1990; Iao?ia ?.A. e ae?., 1994), ui
aecia/athoue ?o ?ieue ye ?ioiieiiiaoaioieo ee?oei (Iie O. e ae?., 1987).
Oiio ci?ia ni?aa?aeiioaiiy iniiaieo noaiiioeyoe?e O -e?ioioeeo?a
ia?eoa?e/ii? e?ia? ? iaeiei c aieiaieo a?iia?ea??a ?aae?aoe?eiiai
o?aaeaiiy i?aai?cio (?iiaiaiei A.A. e ae?., 1989; Aacuea Ae.A., 1996).
Oae? ci?ie iiaeooue aooe i?e/eiith ?icaeoeo iaoieia?/ieo noai?a o
i?aeoe/ii caei?iaeo in?a, ui caciaee aieeao ?ii?coth/iai aei?ii?iaiiy a
iaeeo aeicao, o a?aeaeaeaiee ia??iae i?ney *i?iiaeeuenueei? eaoano?ioe.
Oea coiiaeei iaiao?aei?noue aea/aiiy noaiiioeyoe?eiiai neeaaeo O
-e?ioioeeo?a ia?eoa?e/ii? e?ia? aeaiiai eiioeiaaioo ianaeaiiy ca
aeni?an??th O-ee?oeiieo iiaa?oiaaeo ia?ea??a.

Ca’ycie ?iaioe c iaoeiaeie i?ia?aiaie, ieaiaie, oaiaie. Aeine?aeaeaiiy
i?iaiaeeeeny a ?aieao aeaio aea?aeaaieo oai:

1. “?aaa?e?oaoe?y ?ioiiiai oa oe?ai?aeiiai noaoono ae?oae /a?ac 7-10
?ie?a i?ney aaa??? ia *AAN” — eiiieaenia /ioe?e??/ia IAe? ca?aeii
iaoeiai-oaoi?/ii? i?ia?aie “Caoeno oa ?aaa?e?oaoe?y ?ioiii? nenoaie
ianaeaiiy Oe?a?ie” (?icae?e 1.1.2 “Caei?ia’y ethaeeie”) — ca caiiaeaiiyi
I?i?noa?noaa Oe?a?ie o ni?aaao iaoee ? oaoiieia?e, iiia? aea?aeaaii?
?a?no?aoe?? 01960006767.

2. “Aieea aeaaeai?/ieo iaaaioaaeaiue ia ooieoe?? ?ioiii? nenoaie o
nooaeaio?a, ui caciaee aieeao oaeoi??a aaa??? ia *AAN. Iiooe oeyo?a
cieaeaiiy ?ioiiaeai?aneaii? ae?? aeaaeai?/iiai no?ano” – ca caiiaeaiiyi
I?i?noa?noaa ina?oe Oe?a?ie, iiia? aea?aeaaii? ?a?no?aoe?? 01960006768.

Iaoa aeine?aeaeaiiy: anoaiiaeoe, /e ?nio? iiaeeo?eaoe?y ii??aiyii c
eiio?ieai aeni?an?? O-ee?oeiieo iiaa?oiaaeo ia?ea??a e?ioioeeoaie
ia?eoa?e/ii? e?ia? o i?aeoe/ii caei?iaeo ethaeae, ui caciaee aieeao
?ii?coth/iai aei?ii?iaiiy a iaeeo aeicao aiane?aeie aaa??? ia *AAN, o
a?aeaeaeaiee ia??iae i?ney eaoano?ioe.

Aeey aeinyaiaiiy iaoe aeine?aeaeaiue aoee aecia/ai? ne?aeoth/?
caaaeaiiy:

1. Aeine?aeeoe aeni?an?th iiaa?oiaaeo aioeaai?a O-ee?oei ia?eoa?e/ii?
e?ia? o i?aeoe/ii caei?iaeo in?a c ?aae?aoe?eii iacaa?oaeiaieo ?aeii?a
Oe?a?ie.

2. Aeine?aeeoe aeni?an?th iiaa?oiaaeo aioeaai?a O-ee?oei ia?eoa?e/ii?
e?ia? o i?aeoe/ii caei?iaeo in?a, aaaeoeiaaieo c 30-ei ciie a?ae *AAN
(caciaee ei?ioei/aniiai aino?iai aieeao iaeeo aeic ?aae?aoe?? aiane?aeie
aaa??? ia *i?iiaeeuenuee?e AAN).

3. Aeine?aeeoe aeni?an?th iiaa?oiaaeo aioeaai?a O-ee?oei ia?eoa?e/ii?
e?ia? o i?aeoe/ii caei?iaeo in?a, ui i?iaeeaathoue ia oa?eoi??yo
iineeaiiai ?aae?iaeieia?/iiai eiio?ieth (caciaee o?ii?/iiai aieeao iaeeo
aeic ?aae?aoe?? aiane?aeie aaa??? ia *i?iiaeeuenuee?e AAN).

4. Aeine?aeeoe aieea i?io?eaeoe/iiai eo?no ii?iiaa?e/ii? a?iien?? ia
aeni?an?th iiaa?oiaaeo ia?ea??a O -e?ioioeeo?a ia?eoa?e/ii? e?ia? o
i?aeoe/ii caei?iaeo ianoaaeaieo c eiio?ieueii? a?oie oa in?a, ui caciaee
o?ii?/iiai aieeao iaeeo aeic ?ii?coth/i? ?aae?aoe??.

5. Aeine?aeeoe aieea eiia?iiaaiiai eo?no ii?iiaa?e/ii? a?iien?? oa
i?ia?aei-, iie?a?oai?iioa?ai?? ia aeni?an?th iiaa?oiaaeo ia?ea??a
O-e?ioioeeo?a ia?eoa?e/ii? e?ia? o i?aeoe/ii caei?iaeo ianoaaeaieo c
eiio?ieueii? a?oie oa in?a, ui caciaee o?ii?/iiai aieeao iaeeo aeic
?ii?coth/i? ?aae?aoe??.

Iaoeiaa iiaecia ?iaioe:

1. Aia?oa iieacaii, ui /a?ac 7-10 ?ie?a i?ney aaa??? ia *i?iiaeeuenuee?e
AAN o i?aeoe/ii caei?iaiai ianaeaiiy, ui caciaei aino?iai oa o?ii?/iiai
?aae?aoe?eiiai ii?ii?iaiiy a iaeeo aeicao, o ia?eoa?e/i?e e?ia?
niinoa??aathoueny ci?ie aeni?an?? iiaa?oiaaeo ia?ea??a O-e?ioioeeo?a oa
ni?aa?aeiioaiiy ?o iniiaieo ?aaoeyoi?ieo noaiiioeyoe?e ii??aiyii c
eiio?ieai.

2. Aia?oa aeyaeaii, ui o iieacieeao ee?oeiiiai ?ioi?oaoo a?oi ianaeaiiy,
ui caciaei aieeao iaeeo aeic ?ii?coth/iai aei?ii?iaiiy o ??cieo
?aaeeiao, niinoa??aathoueny a?aei?iiino? uiaei aaniethoiiai /enea c??eeo
O-ee?oei oa iniiaieo ?aaoeyoi?ieo noaiiioeyoe?e.

3. Aia?oa iieacaii, ui i?io?eaeoe/iee eo?n ii?iiaa?e/ii? a?iien?? oa
i?ia?aei-, iie?a?oai?iioa?ai?? ni?ey? ei?aeoe?? iieaciee?a aeni?an??
O-ee?oeiieo iiaa?oiaaeo ia?ea??a e?ioioeeoaie in?a, ui caciaee o?ii?/ii?
ae?? iaeeo aeic ?ii?coth/i? ?aae?aoe??.

I?aeoe/ia cia/aiiy iaea?aeaieo ?acoeueoao?a iieyaa? o oi?ioaaii? ciaiue
i?i aieea iaeeo aeic ?ii?coth/iai aei?ii?iaiiy, o a?aeaeaeaiee ia??iae,
ia iieacieee ee?oeiiiai ?ioi?oaoo ia?eoa?e/ii? e?ia? i?aeoe/ii caei?iaeo
ethaeae, ui iiaea aooe aeei?enoaii a o?c?ieia?? ethaeeie ? oaa?ei,
ii?iaeuei?e o?c?ieia??, iaoieia?/i?e o?c?ieia??, ?aae?ia?ieia??,
aeieia?? ethaeeie, o?c?ieia?? ee?oeie, ?ioiio?c?ieia??. Iieacaia
iiaeeea?noue caoinoaaiiy i?io?eaeoe/ieo naain?a ii?iiaa?e/ii? a?iien??
oa i?ia?aei-, iie?a?oai?iioa?ai?? aeey ei?aeoe?? iieaciee?a ee?oeiiiai
?ioi?oaoo o ianaeaiiy, ui caciaei o?ii?/iiai aieeao iaeeo aeic
?ii?coth/i? ?aae?aoe??.

Iniaenoee aianie caeiaoaa/a o aeeiiaiiy ?iaioe iieyaa? a naiino?eiiio
aeeiiaii? eaai?aoi?ii? /anoeie ?iaioe (aecia/aiiy ??aiy a?eo?ioeeo?a,
aaiiaeia?io, eaeeioeeo?a, e?ioioeeo?a, iieaciee?a aeni?an?? O-ee?oeiieo
iiaa?oiaaeo ia?ea??a), noaoenoe/ii? ia?iaee, iieno ? iaaiai?aiiy
?acoeueoao?a.

Ai?iaaoe?y ?acoeueoao?a aeena?oaoe??. ?acoeueoaoe ?iaioe aeiiia?aeaeeny
ia iaoeiaeo, iaoeiai-i?aeoe/ieo eiioa?aioe?yo oa neiiic?oiao
“?ioaa?aoe?y iaoee a nenoaio i?aeaioiaee a/eoae?a” (*a?eane, 1995),
“Iniaeeaino? oi?ioaaiiy oa noaiiaeaiiy ineoio?c?ieia?/ieo ooieoe?e a
iioiaaiac?” (Ee?a-*a?eane, 1995), “*i?iiaeeue: aeieia?y, i?e?iaea oa
noni?euenoai” (Oiaiue, 1996), “O?ce/ia eoeueoo?a, nii?o oa caei?ia’y”
(*a?eane — Ia?ayneaa-Oiaeueieoeueeee, 1996) “Aaeaioaoe?ei? iiaeeeaino?
ae?oae ? iieiae?” (Iaeana, 1996), “?iaeea?aeoaeuei? ineoio?c?ieia?/i?
aeanoeaino? ethaeeie oa i?ioan?eia ae?yeuei?noue” (Ee?a-*a?eane — 1997),
XV c’?cae? Oe?a?inueeiai o?c?ieia?/iiai oiaa?enoaa (Aeiiaoeuee, 1998).

Ioae?eaoe??. Ca iaoa??aeaie aeine?aeaeaiiy iaae?oeiaaii 14 ?ia?o.

Ianya oa no?oeoo?a aeena?oaoe??. ?iaioa i?noeoue anooi, iaeyae
e?oa?aoo?e, iaoiaeeeo aeine?aeaeaiiy, aeani? aeine?aeaeaiiy oa ?o
iaaiai?aiiy, aeniiaee oa nienie e?oa?aoo?e. Oaeno aeena?oaoe??
aeeeaaeaiee ia 199 noi??ieao iaoeiiieniiai oaenoo. ?iaioa ?ethno?iaaia
31 oaaeeoeath oa 17 ?enoieaie. A?ae?ia?ao?y aeeth/a? 297 aeaea?ae
a?o/eciyii? oa ca?oa?aeii? e?oa?aoo?e.

IAOA??AEE ? IAOIAeE AeINE?AeAEAIIss

Ia’?eo aeine?aeaeaiue: 112 in?a a?eii 18-21 ?ie?a, ui i?iaeeaaee ia
i?ioyc? anueiai aeeooy a iaeiaeiaeo ee?iaoi-aaia?ao?/ieo oiiaao.

Ianoaaeai? aoee ?icae?eai? ia o?e a?oie:

? — i?aeoe/ii caei?ia? iniae, ui i?iaeeaaee ia ?aae?aoe?eii
iacaa?oaeiaieo oa?eoi??yo *a?eanueei?, Iieoaanueei?, E??iaia?aaenueei?
iaeanoae Oeaio?aeueii? Oe?a?ie (“eiio?ieueia a?oia”, 32 iniae);

?? — iniae, aaaeoeiaai? c 30-ei ciie a?ae *AAN (ciia a?ae/oaeaiiy) aei
i. *a?eane o 1986 ?ioe? (c i. I?ei’youe — 27 ea?oiy, c i. *i?iiaeeue — 5
o?aaiy; “aaaeoeiaai?”, 44 iniae). Caciaee aino?iai aieeao iaeeo aeic
?ii?coth/i? ?aae?aoe?? o a?oe? 10-11 ?ie?a. ?iaeea?aeoaeuei? aeice
ii?ii?iaiiy iaa?aeii?. Ca?aaei?e iieaciee ianii?oii? aeice — 18.21 iCa.

??? — iniae, ui i?iaeeaaee a ?aeiiao Oeaio?aeueii? Oe?a?ie c
?aae?aoe?eiei caa?oaeiaiiyi 1-5 Eu/ei2. Caciaaaee o?ii?/iiai aieeao
iaeeo aeic ?ii?coth/i? ?aae?aoe?? o a?oe? a?ae 10 aei 17 ?ie?a
(“iaoeaioe? ?aae?aoe?eii caa?oaeiaieo ?aeii?a”, 37 in?a). Ianii?oi?
aeice ii?ii?iaiiy aeey ianoaaeaieo in?a aeaii? a?oie neeaaeaee 0,21-0,38
iCa o 1991 ?ioe?, 0,12-0,47 iCa o 1994 ?ioe? ? 0,06-0,21 iCa o 1996
?ioe?.

Aeine?aeaeaiiy i?iaiaeeeeny c eenoiiaaeo ii ea?oaiue, /a?ac 6 i?nyoe?a
i?ney inoaiiueiai uaieaiiy. Ee?i?/io oa?aeoa?enoeeo ianoaaeaieo
iaea?aeaee ia iniia? aeieaai?aoi?ii? ae?aaiinoeee. I?iaiaeeany ?o iaeyae
e?ea?ai oa caiiaiaiiy ea?o ?iaeea?aeoaeueiiai ?ioiieia?/iiai eiio?ieth,
?aeiiaiaeiaaieo ?anioae?eainueeei ?ioiieia?/iei oeaio?ii aeey ianiaiai
?ioiieia?/iiai ne?ei?iao. A ianoaaeaieo in?a aoee a?aenooi? o?ii?/i? oa
aino?? ?ani??aoi?i? caoai?thaaiiy.

Aeni?an?th O-ee?oeiieo iiaa?oiaaeo ia?ea??a aecia/aee
?ioiioeoi?anoeaioiei iaoiaeii c aeei?enoaiiyi iiiieeiiaeueieo aioeo?e
CD3 oa CD5 (O-e?ioioeeoe), CD4 oa CD8 (?aaoeyoi?e ?ioiii? a?aeiia?ae?),
CD16 (N — e?ea?e), HLA-DR (ee?oeie, ui aeni?anothoue iieaeoee
a?noinoi?niino?), aeaioiaeaieo a ia’?aeiaii? “Ni?aaio” (?inoeooo
?ioiieia?? ?AII) oa F(ab’)2-o?aaiaio?a aioeo?e aei ?ioiiaeiaoe?i?a ieo?,
iii?/aieo F?TC. Aeey iiaea?eiiai ia?eoaaiiy aeei?enoiaoaaee noi?o
aioeo?e o??ie “Becton D?ck?nson”, i?/aieo oeoi?anoea?iii (F?TC) ?
o?eia?eo?eiii (PA): Ant?-Leu-3a F?TC+Ant?-Leu-2a PE (CD4+CD8);
Ant?-Leu-3a F?TC + Ant?-HLA-DR PE (CD4+HLA-DR); Ant?-Leu-3a
F?TC+Ant?-?L-2 ?E (CD4+CD25); Anti-Leu-4 FITC+Anti-Leu-11c
PE+Anti-Leu-19 PE (CD3+CD16CD56). Ioe?ieo ?aaeoe?? ?ioiioeoi?anoeaioe??
i?iaiaeeee ca aeiiiiiaith i?ioi/iiai oeeoioeoi?eiao?a FACScan (“Becton
D?ck?nson”) oa i?e?ineiio c oeoi?anoeaioiith ianaaeeith EI — 130 IN.

A ianoaaeaieo aea/aee ??aaiue a?eo?ioeeo?a, ai?no aaiiaeia?io o
ia?eoa?e/i?e e?ia? (aaiiaeia?ioe?ai?aeiei iaoiaeii c aeei?enoaiiyi
i?e?iieaeoioiiao?o EOEI-2), ai?no eaeeioeeo?a, a?aeiinio oa aaniethoio
e?euee?noue e?ioioeeo?a. Oiiae ii?iiaa?e/ii? a?iien?? noai?thaaeenue o
eaia?? a??nueeiai iia?o?y “Ai?ae”, ae?iaieoeoaa I?Oe “II?O” IAI Oe?a?ie,
ui aea? a?iiene/io noi?o 10 — 12 % eenith a acio?. Iiaiee naain
neeaaeaany c o?ueio ia??iae?a ii 10 oa, i?ae yeeie aea? ia?a?ae ii 5 oa,
i?ae /an yeeo iaoe??ioe a?aeii/eaaee. Eo?n ii?iiaa?e/ii? a?iien??
neeaaeaany c 10 naain?a.

Aeey aeiaeaoeiaiai eo?no i?ia?aei-, iie?a?oai?iioa?ai?? aeei?enoiaoaaee
i?aia?ao “Aeoia?o” (iaeia ae?aaea a?oai?i?a ? iaeia ae?aaea i?ia?ae?a
iaeei ?ac ia aeaiue, i?ney naaino ii?iiaa?e/ii? a?iien??). Noaoenoe/io
ia?iaeo aeaieo aeine?aeaeaiue oa a?ao?/ia a?aeia?aaeaiiy iaoa??aeo
i?iaiaeeee ia IAII IBM PC/AT 286. Aeey ii??aiyiiy aea??ie
aeei?enoiaoaaee t-e?eoa??e Nouethaeaioa.

?ACOEUeOAOE AeINE?AeAEAIUe OA ?O IAAIAI?AIIss

Aeine?aeaeaiiy aeni?an?? O-ee?oeiieo iiaa?oiaaeo ia?ea??a e?ioioeeoaie o
i?aeoe/ii caei?iaeo in?a c ?aae?aoe?eii iacaa?oaeiaieo ?aa?ii?a
Oeaio?aeueii? Oe?a?ie iieacaee, ui aea/ai? iieacieee ia aeoiaeyoue ca
iaae? ii?ie.

Aeine?aeaeaiiy iieaciee?a ?ioiii? nenoaie ianaeaiiy, ui caciaei aieeao
iaeeo aeic ?ii?coth/i? ?aae?aoe??, iieacaee, ui /a?ac 7-10 ?ie?a i?ney
aaa??? ia *AAN o ianoaaeaieo, aaaeoeiaaieo c 30-ei ciie a?ae ?aaeoi?a
(caciaee ei?ioei/aniiai aino?iai aieeao iaeeo aeic ?ii?coth/i?
?aae?aoe??), a?aei?/a?oueny cieaeaia ii??aiyii c eiio?ieai e?euee?noue
eaeeioeeo?a o ia?eoa?e/i?e e?ia?. A in?a, ui oeae ia??iae i?iaeeaaee ia
oa?eoi??yo c ?aae?aoe?eiei caa?oaeiaiiyi 1-5 Eu/ei2 (caciaee o?ii?/iiai
aieeao iaeeo aeic ?ii?coth/i? ?aae?aoe??) ??aaiue eaeeioeeo?a
noaoenoe/ii aeinoia??ii ia a?ae??ciy?oueny a?ae eiio?ieth.

Anoaiiaeaii, ui a ia?eoa?e/i?e e?ia? aaaeoeiaaieo c 30-ei ciie a?ae *AAN
niinoa??aa?oueny cia/ii i?aeaeuaia ii??aiyii c eiio?ieai aaniethoia oa
a?aeiinia e?euee?noue e?ioioeeo?a. I?ioa, i?aeaeuaiiy aaniethoii?
e?eueeino? e?ioioeeo?a i?e iecueeiio ??ai? eaeeioeeo?a iiaea aooe
iciaeith o?ii?/ii? ?ioaeoe?? (Oiaei?ia E., 1963), oiaoi, ia na?ae/eoue
i?i aeaaiiieo//y ?ioiiiai eiiiiiaioo aiiainoaco. O ianaeaiiy
?aae?aoe?eii caa?oaeiaieo oa?eoi??e Oe?a?ie a?aeiinia oa aaniethoia
e?euee?noue e?ioioeeo?a aoee aeinoia??ii cieaeai?. Oaeei /eiii,
iiaeeo?eaoe?y, ii??aiyii c eiio?ieai, oaeiai iieacieeo ?ioiii? nenoaie,
ye ai?no e?ioioeeo?a o ia?eoa?e/i?e e?ia?, i?e aino?iio oa o?ii?/iiio
?aae?aoe?eiiio ii?ii?iaii? ia? ??ciiiai?aaeaiee oa?aeoa?.

A?aeiii, ui eiaeia O -ee?oeia ia? na?e oaiioei, ui coiiaeth? ?? ooieoe??
ye ?ioiieiiiaoaioii? ee?oeie (Iaiueei A.I. e ae?., 1987; Aa?oeai?a A.A.,
1990; Iie O., 1987; Eiceia E.A. e ae?., 1995) ? aecia/a?oueny ca
aeni?an??th O-ee?oeiieo iiaa?oiaaeo ia?ea??a. I?e i?iaaaeaii?
aeine?aeaeaiue o in?a, ui caciaee aieeao iaeeo aeic ?ii?coth/iai
aei?ii?iaiiy, aoee aeyaeai? ci?ie ii??aiyii c eiio?ieai aeni?an??
iiaa?oiaaeo aioeaai?a O -e?ioioeeo?a. Niinoa??aaeiny noaoenoe/ii
aeinoia??ia cieaeaiiy a?aeiiniiai /enea ee?oei, ui aeni?anothoue
CD3-iai-O-ee?oeiiee ia?ea? o aaaeoeiaaieo c 30-ei ciie a?ae *AAN, ui
caciaee ei?ioei/aniiai aino?iai aieeao iaeeo aeic ?ii?coth/i?
?aae?aoe??. A in?a c ?aae?aoe?eii caa?oaeiaieo oa?eoi??e Oe?a?ie, ui
caciaee o?ii?/iiai aieeao iaeeo aeic ?ii?coth/i? ?aae?aoe??, aeyaeaii
noaoenoe/ii aeinoia??ia cieaeaiiy ye a?aeiiniiai, oae ? aaniethoiiai
/enea ee?oei, ui aeni?anothoue aioeaai CD3, o ii??aiyii? c eiio?ieai.
*a?ac ?aoeaioi?iee eiiieaen CD3-OE? ?aae?co?oueny eeane/iee oeyo
aeoeaaoe?? O-e?ioioeeo?a (Kuvano K. et al., 1994). Cieaeaiiy /enea
ee?oei-aeoeaioi??a aeoeaaoe?? neaiaeo (CD3+) na?ae/eoue i?i aeaye?
ii?ooaiiy a aeaiiio oeyoo ?ioiii? a?aeiia?ae?. E??i oiai,
aeni?anoth/enue ia i?ci?o noaae?yo ?icaeoeo oeiioeeo?a, ?aoeaioi? CD3 ?
iciaeith ooieoe?iiaeueii c??eeo O-e?ioioeeo?a ? ei-?aoeaioi?ii aeey
aioeaai?a CD4 oa CD8 (Iaiueei A.I. e ae?., 1987; ss?eeei A.A. e ae?.,
1990). A?aeiia?aeii, cieaeaiee ai?no ee?oei c oaiioeiii CD3+ iiaea
a?aeia?aaeaoe ci?ie ??aiy iniiaieo noaiiioeyoe?e O -e?ioioeeo?a
ia?eoa?e/ii? e?ia? i?e aino?iio oa o?ii?/iiio aieea? iaeeo aeic
?ii?coth/i? ?aae?aoe??.

Aeine?aeaeaiiy iieacaee, ui a ia?eoa?e/i?e e?ia? aaaeoeiaaieo c 30-ei
ciie a?ae *AAN noaoenoe/ii aeinoia??ii cieaeaia, ii??aiyii c eiio?ieai,
a?aeiinia /enei ee?oei, ui aeni?anothoue ?ioee iai-O-ee?oeiiee ia?ea? —
CD5. O ianaeaiiy ?aae?aoe?eii caa?oaeiaieo oa?eoi??e aeyaeaii
noaoenoe/ii aeinoia??ia cieaeaiiy ye a?aeiiniiai, oae ? aaniethoiiai
/enea ee?oei c oaiioeiii CD5+. O aaaeoeiaaieo c 30-ei ciie a?ae *AAN oa
a in?a, ui caciaee o?ii?/iiai aieeao iaeeo aeic ?aae?aoe??,
niinoa??aa?oueny noaoenoe/ii aeinoia??ia i?aeaeuaiiy ??cieoe? (CD5+ —
CD3+) -e?ioioeeo?a o ia?eoa?e/i?e e?ia?, ui na?ae/eoue i?i a?eueo
ae?aaeaiee oa?aeoa? cieaeaiiy i?ioeaioo e?ioioeeo?a c oaiioeiii ND3+.
Ine?eueee a i?ioean? aeeoa?aioe?thaaiiy ee?oei o oeion? CD5-aioeaai
c’yaey?oueny ?ai?oa, i?ae CD3 -aioeaai (ss?eeei A.A. e ae?., 1990),
iiaeia i?eionoeoe, ui ??cieoey i?ae ??aiai CD5+ oa CD3+ -ee?oei ?
iciaeith oee?eoeyoe?? a ia?eoa?e/i?e e?ia? iaio c??eeo e?ioioeeo?a.
Iayai?noue iac??eeo e?ioi?aeieo oi?i o aaaeoeiaaieo c 30-ei ciie a?ae
*AAN i?aeoaa?aeeeany i?e ioe?ioe? ni?aa?aeiioaiiy iniiaieo noaiiioeyoe?e
O -ee?oei.

Aeni?an?y CD4 oa CD8 -iiaa?oiaaeo ia?ea??a ? caaaeueiiaeciaiith iciaeith
aeaio iniiaieo noaiiioeyoe?e O-ee?oei-?aaoeyoi??a ?ioiii? a?aeiia?ae?
(Sant A. et al., 1994; Mut?s Tuna et al., 1994; Nakamura N. et al.,
1990, 1991;Oeeaoia A.A. e ae?., 1987). Anoaiiaeaii, ui a in?a,
aaaeoeiaaieo c 30-ei ciie a?ae *AAN, niinoa??aa?oueny aeinoia??ia
cieaeaiiy a?aeiinii? e?eueeino? iiiiioeeaa??a, ui aeni?anothoue CD4
-iiaa?oiaaee ia?ea?. A?aeiinia /enei O-ee?oei c oaiioeiii CD8+ a in?a
aeaii? a?oie i?aeaeuaia o ii??aiyii? c eiio?ieai. Ine?eueee o ianaeaiiy,
ui caciaei aino?i? ae?? iaeeo aeic ?ii?coth/i? ?aae?aoe??, i?aeaeuaia
caaaeueia /enei e?ioioeeo?a o ia?eoa?e/i?e e?ia?, aaniethoia e?euee?noue
ee?oei c oaiioeiaie CD4+ oa CD8+ oaeiae i?aeaeuaia. I?ioa, ??no
caaaeueiiai /enea CD8+ -e?ioioeeo?a ia? a?eueo ae?aaeaiee oa?aeoa?. Aeey
ianaeaiiy ?aae?aoe?eii caa?oaeiaieo oa?eoi??e Oe?a?ie oa?aeoa?ia
aeinoia??ia cieaeaiiy ? aaniethoiiai, ? a?aeiiniiai iieaciee?a CD4+
-e?ioioeeo?a. Aaniethoia /enei ee?oei c oaiioeiii ND8+ cieaeaia,
a?aeiinia aeinoia??ii i?aeaeuaia. A caaaeueiiio, ye o aaaeoeiaaieo c
30-ei ciie a?ae *AAN, oae ? o iaoeaioe?a ?aae?aoe?eii caa?oaeiaieo
?aa?ii?a a?aei?/a?oueny cieaeaiiy ii??aiyii c eiio?ieai
?ioii?aaoeyoi?iiai ?iaeaeno (CD4+/CD8+). I?e/eia cieaeaiiy ??aiy CD4+
-e?ioioeeo?a o ianoaaeaieo c iaio a?oi ia iiaea aooe coiiaeaia
i?aeaeuaiith ?aae?i/ooeea?noth oe??? noaiiioeyoe??, ine?eueee c
e?oa?aoo?e a?aeiii, ui CD4+ ? CD8+ -ee?oeie iathoue iaeiaeiao
/ooeea?noue aei ?ii?coth/iai aei?ii?iaiiy (Nakamura N. et al., 1990;
Uzawa A. et al., 1994). Iiaeeeai, a aeaiiio aeiaaeeo ia? i?noea oaeo
?nioaaiiy iaaieo ii?ooaiue O-ee?oeiieo aeeoa?aioe?thaaeueieo i?ioean?a,
coiiaeaieo ye aino?ei, oae ? o?ii?/iei aieeaii iaeeo aeic ?aae?aoe??.
Oai?aoe/iei iioeaii aeey iiae?aiiai aeniiaeo ? aeine?aeaeaiiy McDonagh
M. et al. (1985) i?i ?aaoeyoi?io eiiiainaoe?th iaaeinoa/? CD4+
e?ioioeeo?a ca ?aooiie iiaeeo?eaoe?? CD8 -iiaa?oiaaiai ia?ea?a. I?i
iiaeeea?noue ia?aoai?aiiy CD8+ e?ioioeeo?a a ee?oeie, ui ianooue CD4
-iiaa?oiaaee aioeaai, iia?aeiieya oaeiae Parham Peter et al.
(1992).Oaiiiai coiiaeaiee oei, ui CD4 ? CD8 -aioeaaie ? aca?iii
o?aineieiaaieie aa?n?yie. A oeueiio iaia? i?/iai aeeaiiai, yeui caaaeaoe
ni?euei?noue iioiaeaeaiiy oa oaiioeio iiia?aaeiee?a O -oaeia?ieo oa O
-noi?ani?ieo ee?oei (Penit N. et a?., 1988; Lukas A. et al., 1994;
Marodon G. et al., 1994). Aeey ca’ycoaaiiy aioeaai?a AEAN eeano II, CD4
-aioeaaie iathoue Ig-iiae?ai? aeiiaie, ui ooai?ththoue aeoyaiooo
no?oeoo?o “rod“. I?e iaaieo oiiaao iie?iaioeaeiee eaioethaeie iiaea
i?eeiaoe eiio?ao?aoe?th “box““, yea ca”yco? aioeaaie AEAN eeano I.
Oiaoi, a oae?e neooaoe?? ?aoeaioi? ia? no?oeoo?io iniiao CD8. Oea
i?aeo?eio? iaaiee e?euee?niee ??aaiue ?aaoeyoi?ieo noaiiioeyoe?e ?
aeao?oeeo ee?oei-oaeia??a eiiiaino?oueny caaaeyee o?aineieaoe??
CD8-?aoeaioi?a(Parham P.et al., 1992). C e?oa?aoo?ieo aeaea?ae a?aeiii,
ui ii?ooaiiy ni?aa?aeiioaiiy O-ee?oei c oaiioeiaie CD4+ oa CD8+ ia
ei?enoue CD8+-eiioooeeoia ? iaei??th c ia?oeo iciae, ui na?ae/aoue i?i
i?eai?/aiiy ?ioiii? nenoaie i?e ?? noa??ii? (Aaeyeia E.I. e ae?., 1993;
Barrat F. et al., 1995). Iiaeeeai, cieaeaiiy ?iaeaeno ?ioii?aaeoeaiino?
aoei aieiaiith i?e/eiith ?icaeoeo ?ioaeoe?eieo neiae?ii?a, aeyaeaieo i?e
ee?i?/iiio ianoaaeaii? ianaeaiiy, ui caciaei ae?? iaeeo aeic
?ii?coth/iai aei?ii?iaiiy. O ianoaaeaieo a?aei?/aeiny aeayea i?aeaeuaiiy
/anoioe aino?eo oa i?ieiiaiaaieo ?ani??aoi?ieo caoai?thaaiue.

Aeni?an?y CD4 oa CD8 -iiaa?oiaaeo ia?ea??a ua ia ? iciaeith c??ei?
ee?oeie c ooieoe?yie O-oaeia?a /e O-noi?ani?a. A?aeiii, ui a i?ioean?
aeeoa?aioe?thaaiiy oeionicaeaaei? e?ioioeeoe i?ioiaeyoue ne?aeoth/?
aeeoa?aioe?thaaeuei? aoaie : CD4-8-, CD4+8+, CD4+8-, CD4-8+(iiaea?ei?
iaaaoeai?, iiaea?ei? iiceoeai?, iaeeia?i? iiceoeai? ee?oeie) (McDonagh
I. et al., 1985; ss?eeei A.A. e ae?., 1990). Oiio iaie i?iaiaeeeinue
aea/aiiy ni?eueii? aeni?an?? aeuacaaaeaieo ia?ea??a. Anoaiiaeaii, ui o
ianaeaiiy ?aae?aoe?eii caa?oaeiaieo oa?eoi??e niinoa??aa?ouey
ca?eueoaiee, ii??aiyii c eiio?ieai, i?ioeaio ee?oei c oaiioeiii
CD4+CD8+. ?niothoue aeai? i?i i?aeaeuaio /ooeea?noue oeeo ee?oei aei
OE?-?iaeoeiaaii? (aiiioicii?) nia?o? (Kishimoto I. et al, 1995, Kisielow
?. et al., 1995; McConkey O.J. et al., 1994). Aaaaea?oueny, ui
i?aeaeuaiiy ??aiy iiiiioeeaa??a ia?eoa?e/ii? e?ia?, noeeueieo aei
aiiioico, o ianaeaiiy oa?eoi??e, caa?oaeiaieo ?aae?iioee?aeaie, iineoue
aaeaioaoe?eii-caoeniee oa?aeoa?. ?? ?acoeueoaoii ? ae?i?iaoe?y aaiaoe/ii
ianoaa?eueieo ee?oei a oiiaao iino?eiiai ?aae?aoe?eiiai aieeao
(Aa?aiaiei E.A. e ae?., 1996). C ?ioiai aieo, yeui ae?i?iaoe?y
noino?oueny ooieoe?iiaeueii-aaaeeeaeo O-e?ioioeeo?a, iane?aeeii ?o
cieaeaiiy iiaeooue aooe aoi?eii? ?ioiiaeao?oeeoi? noaie (Aacuea
Ae.A.,1996). E??i oiai, iao? aeine?aeaeaiiy na?ae/aoue i?i oaiaeaioe?th
aei cieaeaiiy ai?noo a ia?eoa?e/i?e e?ia? in?a c ?aae?aoe?eii
caa?oaeiaieo ?aa?ii?a Oe?a?ie e?ioi?aeieo ee?oei c oaiioeiii CD4-CD8-,
oiaoi, iaea?eueo ?aae?i?acenoaioii? noaiiioeyoe?? oei?/ieo ai?a?aio?a
(Oa?/aiei O.TH. oa ?i., 1994).

?nio? oi/ea ci?o, ui ?aae?aoe?eiee aieea coiiaeth? ?icaeoie
aeoeaaoe?eieo i?ioean?a a ee?oeiao ?ioiii? nenoaie (Etha/aiei I.I. e
ae?., 1990; Aaeyeia E.I. e ae?., 1993; Aeenaaaa I.A. e ae?., 1994). Oiio
aoei i?iaaaeaii ioe?ieo aeni?an?? iiaa?oiaaeo ia?ea??a, ui
oa?aeoa?ecothoue aeoeaaoe?ei? i?ioeane a O-e?ioioeeoao ia?eoa?e/ii?
e?ia? ianaeaiiy ?aae?aoe?eii caa?oaeiaieo ?aa?ii?a Oe?a?ie. Anoaiiaeaii,
ui a in?a aeaii? a?oie ia? i?noea oaiaeaioe?y aei i?aeaeuaiiy i?ioeaioo
HLA-DR+ -ee?oei. Aeai? e?oa?aoo?e na?ae/aoue i?i i?aeaeuaiiy ai?noo
e?ioioeeo?a c oaiioeiii HLA-DR+ i?e iaaieo caoai?thaaiiyo (Oii/aieiaa
I.A. e ae?., 1995; Eaoeia A.A. e ae?., 1995) oa i?e ?aaaia?aoe?eieo
i?ioeanao (Aaaaaaa A.A., 1985). A iaoeo aeine?aeaeaiiyo niinoa??aa?oueny
ca?eueoaiiy, ii??aiyii c eiio?ieai, /enea HLA-DR+ -ee?oei, ui
aeni?anothoue aioeaai CD4, oiaoi, CD4+HLA-DR+ -ee?oei. A?aeiii, ui
iaiiie?ii?oia ae?eyiea DR iieaeoee eeano ??, aca?iiae?th/e c
CD4-?aoeaioi?ii, i?ecaiaeeoue aei iineeaiiy i?aeee?oeiii? aaeaac?? ?
noeioeyoe?? O-ee?oei (Leahy D.J., 1995). I?e oeueiio a?aeaoaa?oueny
ia?ao?ae O-e?ioioeeo?a c G0 a G1 oaco ee?oeiiiai oeeeeo. A oie aea /an,
a in?a, ui caciaee o?ii?/ii? ae?? iaeeo aeic ?ii?coth/i? ?aae?aoe??,
a?aei?/a?oueny cieaeaiiy /enea ee?oei c oaiioeiii CD4+HLA-DR- o
i?eoa?e/i?e e?ia?. Oae? e?ioioeeoe aieiae?thoue ae?aaeaiith noi?ani?iith
ooieoe??th, ui i?iyaey?oueny a iaiaaeaii? iaoa?io oeeoie?i?a o oiae?
aioeaaiii? noeioeyoe?? (Wysscorray T. et al., 1993). Oiio cieaeaiiy ?o
??aiy, ii?yae ?c i?aeaeuaiiyi /enea ee?oei c oaiioeiii CD4+HLA-DR+,
na?ae/eoue ia ei?enoue a?iioace noeioeyoe?? aeoeaaoe?eieo i?ioean?a a
O-e?ioioeeoao i?e o?ii?/iiio aieea? iaeeo aeic ?aae?aoe??.

O ?acoeueoao? i?iaaaeaiiy aeine?aeaeaiue anoaiiaeaii, ui a in?a, ui
i?iaeeaaee ia i?ioyc? 7-10 ?ie?a ia oa?eoi??yo c caa?oaeiaiiyi 1-5
Eu/ei2 , niinoa??aa?oueny ca?eueoaiiy i?ioeaioo e?ioioeeo?a c oaiioeiii
CD4+CD25+. Oae? e?ioioeeoe neioacothoue ?E-2, ui ni?ey? i?ioiaeo ee?oei
a S -oaco ee?oeiiiai oeeeeo, c iine?aeoth/ith ee?oeiiith ?aie?eaoe??th
(Abbas A.K. et al., 1991). Oiaoi, ?aae?co?oueny ae?oaee aeoeaaoe?eiee
aoai a O-e?ioioeeoao (V?ncent C. et al., 1995).

Oaeei /eiii, aeai? iaoeo aeine?aeaeaiue aeathoue iniiao aeey i?eiouaiiy,
ui o?ii?/ia ii?ii?iaiiy iaeeie aeicaie ?ii?coth/i? ?aae?aoe?? ni?ey?
aeoeaaoe?? O -e?ioioeeo?a. I?ioean i?ioiaeeoue ia o?eueee ca ?aooiie
noeioeyoe?? o?eaa?ieo i?ioean?a, ui coiiaeththoue i?ioiaeaeaiiy
ee?oeiaie G0 — G1 oace ee?oeiiiai oeeeeo, aea e aeoeaaoe?? iine?aeoth/eo
aoai?a ee?oeiii? i?ie?oa?aoe?? (aeoeao?oueny i?io?ae S-oace ee?oeiiiai
oeeeeo). Oea ia iciaea ?ioiiiai aeaaiiieo//y a iiioeyoe??, i?i ui
na?ae/eoue i?aeaeuaiiy ??aiy ?ioaeoe?eieo caoai?thaaiue o a?oi?
ianaeaiiy ?aae?aoe?eii caa?oaeiaieo oa?eoi??e. Iiaeia c?iaeoe
i?eiouaiiy, ui aeoeaaoe?y O-e?ioioeeo?a a in?a, ui caciaee o?ii?/iiai
aieeao iaeeo aeic ?aae?aoe??, i?eaiaeeea aei ?icaeoeo i?ioean?a, ui
ni?eyee caaeaae? e?ioi?aeieo ee?oei. Oea i?aeoaa?aeaeo?oueny cieaeaiiyi
aaniethoii? oa a?aeiinii? e?eueeino? e?ioioeeo?a a in?a, ui caciaee
o?ii?/iiai aieeao iaeeo aeic ?ii?coth/i? ?aae?aoe??. E??i oiai, a?aeiii,
ui a S -oac? ee?oeiiiai oeeeeo e?ioioeeoe /ooeea? aei OE?-?iaeoeiaaii?
nia?o?, aai aiiioico (Boehme S.A. et al., 1993). I?aeaeuaiiy aeni?an??
CD25 -aioeaaio CD4+ -e?ioioeeoaie, ia ia?oiio aoai?, ae?enii i?eaiaeeoue
aei neioaco ?E-2 oa aeoeaaoe?? i?ie?oa?aoe?? ee?oei, aea a
iine?aeoth/iio — ?aae?caoe?y iineethth/iai aoaeoo ?E-2 i?iyaey?oueny a
?iaeoeoe?? i?ioean?a aiiioico a c??eeo O-e?ioioeeoao (Lenardo M.J.,
1991). E?oa?aoo?i? aeai? na?ae/aoue i?i iniaeeao /ooeea?noue O
-e?ioioeeo?a, ui aeni?anothoue CD4 -iiaa?oiaaee ia?ea?, aei
aioeaai-caeaaeiiai aiiioico (D?somma M.M. et al., 1995). I?e ?icaeoeo
?ioaeoe?eieo i?ioean?a oey /ooeea?noue i?aeaeuo?oueny (Boehme S.A. et
al., 1994). C ?ioiai aieo, CD8+ -e?ioioeeoe aaaaeathoue iani?eeiyoeeaeie
aei OE? –?iaeoeiaaii? nia?o? (Akbar A.N. et al., 1993). Oeae oaeo iiaea
aooe iaeiei ?c iiyniaiue ianeio?iiiino? a ci?iao /enea ee?oei c
oaiioeiii CD4+ oa CD8+ (?, ye iane?aeie, cieaeaiiy ?ioii?aaoeyoi?iiai
?iaeaeno (CD4+/CD8+) o ianoaaeaieo, ui caciaee o?eaaeiai aieeao iaeeo
aeic ?ii?coth/iai aei?ii?iaiiy (ia i?ioyc? 7-10 ?ie?a).

Ca?aeii e?oa?aoo?ieo aeaieo, o a?eueoino? in?a, ui caciaee ae??
?ii?coth/iai aei?ii?iaiiy, iaa?oue /a?ac ?noioiee /an i?ney ae??
iiae?acieea ia niinoa??aaeiny a?aeiiaeaiiy e?eueeino? oa aeoeaiino?
iaoo?aeueieo e?ea?ieo ee?oei (Eiienna?aiei N.A. e ae?., 1994; Aacuea
Ae.A., 1996). O ioneiaiio iaoai?ci? e?eeiao IE -ee?oei aioeo?eicaeaaeii?
ee?oeiii? oeeoioiene/iino?, a oaeiae nae?aoe?? oeeoie?i?a iai?aia oa
aeeeth/ia cia/aiiy ia? ?aoeaioi? CD16 (Wh?tes?de T.L. et al., 1994). I?e
i?iaaaeaii? aeine?aeaeaiue aeni?an?? oeueiai aioeaaio e?ioioeeoaie in?a
c ?aae?aoe?eii caa?oaeiaieo ?aa?ii?a iaie anoaiiaeaii, ui i?ioeaio
e?ioioeeo?a c oaiioeiii CD16+ o ia?eoa?e/i?e e?ia? noaoenoe/ii
aeinoia??ii ia a?ae??ciy?oueny a?ae eiio?ieueieo iieaciee?a, aaniethoia
/enei ia? oaiaeaioe?th aei cieaeaiiy. A?aeiii, ui i?enooi?noue ia?ea?o
CD16 iiaea aooe iciaeith aeaio ooieoe?iiaeueii ??cieo noaiiioeyoe?e —
CD3+16+56+ (oeeoie?oe/i? ee?oeie) oa CD3-16+56+ (iaoo?aeuei? e?ea?e)
(Kuvano K. et al., 1994; De Sanct?s J.B. et al., 1995).
Oeeoioeoi?eiao?e/iee aiae?c c iiaea?eiei ia?eoaaiiyi o iaoeo aeine?aeao
iieacaa, ui a iaoeaioe?a ?aae?aoe?eii caa?oaeiaieo ?aa?ii?a
niinoa??aa?oueny cieaeaiiy i?ioeaioo iaoo?aeueieo e?ea?ieo ee?oei ia
oii? noaeiai /enea oeeoie?oe/ieo O -e?ioioeeo?a. Oaeei /eiii, iiaeia
c?iaeoe aeniiaie, ui ianiaoeeo?/ia eaiea ?ioi?oaoo, yea i?aaenoaaeaia
ee?oeiaie-e?ea?aie, ia aaeaioo?oueny aei ae?? iaeeo aeic ?ii?coth/iai
aei?ii?iaiiy. Ine?eueee iaoo?aeuei? e?ea?i? ee?oeie ?aae?cothoue
ianiaoeeo?/iee iaoai?ci ?ioiiiai iaaeyaeo i?ioe ?icaeoeo ceiye?nieo
iiaiooai?aiue, a??onieo oa aaeoa??aeueieo ?ioaeoe?e, ?nio? i?aenoaaa
aeoiaoe, ui oa?eoi??? iineeaiiai ?aae?iaeieia?/iiai eiio?ieth ? ciiith
?eceeo aeey ?icaeoeo ?aeiaeo iooeei oa a??onieo caoai?thaaiue.

Oaeei /eiii, o ianaeaiiy oeaio?aeueieo ?aa?ii?a Oe?a?ie, ui caciaee ae??
oaeoi??a aaa??? ia *AAN o a?aeaeaeaiee ia??iae (/a?ac 7-10 ?ie?a),
niinoa??aa?oueny aaeueioaaiiy ee?oeiii? eaiee ?ioi?oaoo, ui
i?iyaey?oueny o cieaeaii? i?ioeaioo ee?oei, ui aeni?anothoue CD3, CD5,
CD4 oa CD16CD56 -iiaa?oiaa? ia?ea?e. Oaeee noai ee?oeiiiai ?ioi?oaoo o
cia/ii? e?eueeino? iaoeaioe?a e?a?ie coiiaea iiooe oeyo?a ?aaa?e?oaoe??
ooieoe?e ?ioiii? nenoaie ianaeaiiy Oe?a?ie. I?e i?iaaaeaii? iiooeiaeo
aeine?aeaeaiue ie a?aee aei oaaae aeai? Ia??niia O.C. (1987) i?i
?ioiinoeioethth/ee aoaeo ei?ioei/anieo no?aniaeo aieea?a. A yeino?
ianiaoeeo?/iiai iiae?acieea ?ioiii? nenoaie iiaea aenooiaoe ii?iiaa?e/ia
a?iien?y, ui coiiaeth? “i’yeee” iiaeoethth/ee aieea. Ia aeaiee /an aaea
i?iaaaeai? aenia?eiaioe, ui aeyaeee ii?iae?caoe?th iieaciee?a ?ioiii?
nenoaie o e?ea?aeaoi??a aaa??? ia *i?iiaeeuenuee?e AAN i?ney i?iaaaeaiiy
eo?no a?iieneoa?ai?? (Na?aa?ianeay O.A. e ae?., 1996; Na?aa?ianeay C.A.
e ae?., 1996). Iaie i?iaaaeaii aeine?aeaeaiiy aieeao ii?iiaa?e/ii?
a?iien?? ia aaiaoieia?/i? oa ?ioii? iieacieee a in?a, ui caciaee
o?ii?/ii? ae?? iaeeo aeic ?ii?coth/i? ?aae?aoe?? oa ianaeaiiy
?aae?aoe?eii iacaa?oaeiaieo ?aa?ii?a Oe?a?ie.

Anoaiiaeaii, ui a in?a c eiio?ieueii? a?oie oa ianaeaiiy ?aae?aoe?eii
caa?oaeiaieo ?aeii?a Oe?a?ie i?ney i?io?eaeoe/iiai eo?no ii?iiaa?e/ii?
a?iien?? niinoa??aathoueny iaai? ci?ie aaiaoieia?/ieo iieaciee?a.
Cie?aia, noaoenoe/ii aeinoia??ii c?inoa? /enei a?eo?ioeeo?a oa ??aaiue
aaiiaeia?io a ia?eoa?e/i?e e?ia? ianoaaeaieo c iaio a?oi. ?acoeueoaoe
na?ae/aoue i?i aeoeaaoe?th e?iaioai?ii? ooieoe?? e?noeiaiai iiceo
aiane?aeie cieaeaiiy ia?oe?aeueiiai oeneo eenith, ui a?aeiia?aea?
e?oa?aoo?iei aeaiei (Oaeaineee ss.A., 1968; Niaieaa A.A. e ae?., 1992).
Niinoa??aa?oueny oaeiae noaoenoe/ii aeinoia??ia i?aeaeuaiiy aaniethoiiai
oa a?aeiiniiai /enea e?ioioeeo?a i?e noaeiio ??ai? eaeeioeeo?a a in?a,
ui caciaee o?ii?/iiai aieeao iaeeo aeic ?aae?aoe??. Ia a?aei?io a?ae
oeueiai, aiaeia?/i? iieacieee a in?a c eiio?ieueii? a?oie i?ney
a?iieneoa?ai?? caeeoeeeny i?aeoe/ii aac ci?i.

Aea/aiiy iieaciee?a ee?oeiiiai ?ioi?oaoo ianoaaeaieo, ui i?ieoee eo?n
ii?iiaa?e/ii? a?iien??, iieacaei iayai?noue iaaieo e?euee?nieo ci?i
noaiiioeyoe?e e?ioi?aeiiai ?yaeo. O ianaeaiiy ?aae?aoe?eii caa?oaeiaieo
oa?eoi??e i?aeaeuo?oueny aaniethoia oa a?aeiinia /enei ee?oei c
oaiioeiaie CD3+, CD4+, CD5+. Oea coiiaeth? ?o o/anoue o O -ee?oeii?e
?ioii?e a?aeiia?ae? ? i?eaiaeeoue aei ei?aeoe?? ?aaoeyoi?ii? eaiee
ee?oeiiiai ?ioi?oaoo (?inoo CD4+/CD8+-?ioii?aaoeyoi?iiai ?iaeaeno).
Niinoa??aa?oueny i?aeaeuaiiy caaaeueiiai ??aiy CD16+ -e?ioioeeo?a oa
cieaeaiiy i?ioeaioo HLA-DR+ -ee?oei o ia?eoa?e/i?e e?ia? ianoaaeaieo, ui
caciaee o?ii?/iiai aieeao iaeeo aeic ?ii?coth/i? ?aae?aoe??, i?ney eo?no
a?iieneoa?ai??. Oea iiceoeaiee iiiaio, ine?eueee e?ea?i? ee?oeie
a?ae?a?athoue i?ia?aeio ?ieue a ?aae?caoe?? ooieoe?e i?ioeiooeeiiiai
?ioi?oaoo (Wh?tes?de T.L. et al., 1994) a i?aeaeuaiee ai?no ee?oei c
oaiioeiii HLA-DR+ iiaea na?ae/eoe i?i iayai?noue iaaieo caoai?thaaiue
(Oii/aieiaa I.A. e ae?., 1995; Eaoeia A.A. e ae?., 1995).

Aeey /anoeie in?a c ?aae?aoe?eii caa?oaeiaieo ?aa?ii?a eo?n
ii?iiaa?e/ii? a?iien?? aoei aeiiiaiaii i?ia?aei-, iie?a?oai?iioa?ai??th.
?acoeueoaoe noiae? c io?eiaieie i?e naiino?ei?e a?iieneoa?ai??.
Niinoa??aa?oueny aeaui aeua noaoenoe/ia aeinoia??i?noue ?inoo
a?aeiiniiai oa aaniethoiiai /enea ee?oei c oaiioeiii CD3+ i?ney
eiia?iiaaiiai ?ioiiiiaeoethth/iai eo?no. I/aaeaeii, aeiaeaoeiaee eo?n
i?ia?aei-, iie?a?oai?iioa?ai?? ni?ey? iineeaiith i?ioean?a
aeeoa?aioe?thaaiiy ee?oei, ui aeni?anothoue CD3-iai-O-ee?oeiiee ia?ea?.
A?aeiia?aeii, ei?eao?oueny eeane/iee oeyo aeoeaaoe?? O-e?ioioeeo?a,
ii?ooaiiy yeiai aeyaeee a in?a, ui caciaee o?ii?/iiai aieeao iaeeo aeic
?aae?aoe??.

Anoaiiaeaii, ui noeioeyoe?y aeeoa?aioe?thaaiiy e?ioi?aeieo ee?oei
aiane?aeie eiia?iiaaiiai eo?no ii?iiaa?e/ii? a?iien?? oa i?ia?aei-,
iie?a?oai?iioa?ai??, i?iaaaeaiiai i?ae /an aecaiaiaoe?eii? nan??, o
iaoeaioe?a ?aae?aoe?eii caa?oaeiaieo ?aa?ii?a aaeueio?oueny
ineoiaiioe?eiei iaaaioaaeaiiyi. Iayai?noue no?aniai? neooaoe??
i?aeoaa?aeaeoaaeanue i?aeaeuaiiyi ai?noo ei?oecieo a ia?eoa?e/i?e e?ia?.
Aaeueioaaiiy noeioeyoe?? i?iyaey?oueny o a?aenooiino? aeinoia??ieo ci?i
aeni?an?? CD3 -iai-O-ee?oeiiiai ia?ea?o, cieaeaii? a?aeiiniiai /enea
ee?oei, ui aeni?anothoue CD5 oa CD4 -O-ee?oeii? ia?ea?e. A oie aea /an,
niinoa??aa?oueny oaiaeaioe?y aei ?inoo a?aeiiniiai iieacieea O
-e?ioioeeo?a c oaiioeiii CD8+. sseui ni?aa?aeiioaiiy ee?oei-?aaoeyoi??a
?ioiii? nenoaie a?aeaoaa?oueny ca ?aooiie aca?iii? o?aineieaoe??
aioeaai?a CD4 oa CD8, i?i ui na?ae/aoue aeai? e?oa?aoo?e (McDonagh M. et
al., 1985; Parham P. et al., 1992), a oiiaao ineoi-aiioe?eiiai
iaaaioaaeaiiy oeae i?ioean i?ioiaeeoue ia ei?enoue e?ioioeeo?a c
oaiioeiii CD8+. A caaaeueiiio, i?aeaeuaiiy aeni?an?? ia?ea?o CD8, ia
oii? cieaeaiiy aeni?an?? ND4-iiaa?oiaaiai ia?ea?o, i?eaiaeeoue aei
noaoenoe/ii aeinoia??iiai ciaioaiiy ?ioii?aao eyoi?iiai ?iaeaeno
CD4+/CD8+.

AENIIAEE

1. Ieoaiiy i?i noai ?ioiii? nenoaie o ianaeaiiy Oe?a?ie ca oiia ae??
oaeoi??a aaa??? ia *AAN aea/aia iaaeinoaoiuei. Iaoeiaee oa i?aeoe/iee
?ioa?an noaiiaeyoue aeine?aeaeaiiy aeni?an?? O-ee?oeiieo iiaa?oiaaeo
ia?ea??a e?ioioeeoaie ia?eoa?e/ii? e?ia? o i?aeoe/ii caei?iaeo
iaoeaioe?a Oe?a?ie, ui caciaee aieeao iaeeo aeic ?ii?coth/iai
ii?ii?iaiiy aiane?aeie aaa??? ia *AAN, o a?aeaeaeaiee ia??iae i?ney
eaoano?ioe. Aaaeeeaei oaeiae ? aea/aiiy aieeao ia caaaeai? iieacieee
ianiaoeeo?/ieo ?ioiiiiaeoeyoi??a.

2. Aeey ae??oaiiy iinoaaeaieo ieoaiue aeei?enoiaoaaee
?ioiioeoi?anoeaioiee iaoiae c canoinoaaiiyi iiiieeiiaeueieo aioeo?e aei
iiaa?oiaaeo aioeaai?a O-e?ioioeeo?a ia?eoa?e/ii? e?ia?.

3. ??aaiue eaeeioeeo?a, a?aeiinia, aaniethoia e?euee?noue e?ioioeeo?a oa
?o iniiaieo noaiiioeyoe?e o ia?eoa?e/i?e e?ia? 18-21-??/ieo iaoeaioe?a
?aae?aoe?eii iacaa?oaeiaieo ?aeii?a Oeaio?aeueii? Oe?a?ie ciaoiaeyoueny
a iaaeao ii?ie.

4. *a?ac 7-10 ?ie?a i?ney aaa??? ia *AAN o ianaeaiiy, ui caciaei aieeao
iaeeo aeic ?ii?coth/iai aei?ii?iaiiy o ??cieo ?aaeeiao,
niinoa??aathoueny a?aei?iiino? uiaei aaniethoiiai /enea c??eeo O-ee?oei
oa iniiaieo ?aaoeyoi?ieo noaiiioeyoe?e o ia?eoa?e/i?e e?ia?.

5. A in?a, ui caciaee aino?iai oa o?ii?/iiai aieeao iaeeo aeic
?ii?coth/iai aei?ii?iaiiy, niinoa??aa?oueny cieaeaiiy ii??aiyii c
eiio?ieai aeni?an?? CD3 oa CD5 iai-O-ee?oeiieo ia?ea??a e?ioioeeoaie
ia?eoa?e/ii? e?ia?.

6. Niinoa??aathoueny a?aeoeeaiiy a ?aaoeyoi?i?e eaioe? ee?oeiiiai
?ioi?oaoo ianoaaeaieo, ui caciaee aieeao iaeeo aeic ?ii?coth/iai
aei?ii?iaiiy o ??cieo ?aaeeiao. Aoaeo i?iyaey?oueny o cieaeaii? ?iaeaeno
?ioii?aaeoeaiino? CD4+/CD8+, coiiaeaiiai cieaeaiiyi ii??aiyii c
eiio?ieai i?ioeaioo O-ee?oei c oaiioeiii CD4+ oa i?aeaeuaiiyi i?ioeaioo
e?ioioeeo?a c oaiioeiii CD8+ o ia?eoa?e/i?e e?ia?.

7. O ianaeaiiy, ui caciaei o?ii?/iiai aieeao iaeeo aeic ?aae?aoe??,
a?aei?/a?oueny i?aeaeuaiiy aeni?an?? ia?ea??a aeoeaaoe?? O-ee?oei —
aioeaai?a CD25 oa HLA-DR ia CD4+ -e?ioioeeoao oa cieaeaiiy i?ioeaioo
iaoo?aeueieo e?ea?ieo ee?oei c oaiioeiii CD3-CD16+CD56+.

8. A in?a, ui caciaee o?ii?/iiai aieeao iaeeo aeic ?aae?aoe??,
i?io?eaeoe/iee eo?n ii?iiaa?e/ii? a?iien?? oa i?ia?aei-,
iie?a?oai?iioa?ai?? ni?ey? ei?aeoe?? iieaciee?a O-ee?oeiiiai ?ioi?oaoo,
ui i?iyaey?oueny o ca?eueoaii? a?aeiinii? oa aaniethoii? e?eueeino?
ee?oei, ui aeni?anothoue CD3, CD5 oa CD4 -iiaa?oiaa? aioeaaie.

NIENIE I?AOeUe, IIOAE?EIAAIEO CA

OAIITH AeENA?OAOe??

1. Nieieaiei A.E. ??aaiue e?ioioeeo?a-oaeia??a o in?a, ui caciaee
o?ii?/iiai aieeao iaeeo aeic ?aae?aoe?? // I?aoe? eiioa?aioe??
“?ioaa?aoe?y iaoee a nenoaio i?aeaioiaee a/eoae?a” — *a?eane, 1995.
-N.264-267.

2. Nieieaiei A.E., Iae??iei I.O. Aeni?an?y CD8 -aioeaaio e?ioioeeoaie a
in?a, ui caciaee aieeao ?ii?coth/iai aei?ii?iaiiy // I?aoe? eiioa?aioe??
“?ioaa?aoe?y iaoee a nenoaio i?aeaioiaee a/eoae?a” -*a?eane, 1995.
-N.238-241.

3. Aa?aa I.A., Nieieaiei A.E. Iiaeeo?eaoe?? ani?an?? CD3, CD4 oa
CD8-iiaa?oiaaeo ia?ea??a iiiiioeeaa?aie ia?eoa?e/ii? e?ia? o in?a, ui
caciaee aieeao ?ii?coth/iai ii?ii?iaiiy // Oe?a?inueeee ?aae?ieia?/iee
AEo?iae — 1996. — N1. — N.59-61.

4. Bayeva O.V., Boyechko F.F., Socolenko V.L., Meln?k S.G. Evaluat?on of
the lymphocyte surfase markers assays for b?olog?cal mon?tor?ng of
rad?at?on-exposed people ?njured atom?c acc?dent ?n Chernobyl //
B?olog?cal Mon?tor?ng ?n Occupat?onal and Env?ronmental Health.: Espoo,
F?nland, 1996. — ?. 219-220.

5. Aaaaa A.A., Nieieaiei A.E. Aeni?anney O-eeaoi/iuo iiaa?oiinoiuo
ia?ea?ia eeioioeeoaie eeoe, iiaeaa?aoeony aeeyieth iaeuo aeic ?aaeeaoeee
// Eiioiieiaey — 1998. — N3. — N. 56-59.

6. Aaaaa A.A., Nieieaiei A.E., Aacuea Ae.A. Iiaeeoeeaoeey yeni?annee
O-eeaoi/iuo aeoeaaoeeiiiuo ia?ea?ia eeioioeeoaie ia?eoa?e/aneie e?iae
eeoe, i?iaeeaathueo ia ?aaeeaoeeiiii caa?yciaiiuo oa??eoi?eyo //
?aaeeaoeeiiiay aeieiaey. ?aaeeiyeieiaey — 1998. — O. 38., aui. 6. — N.
869-874.

7. Aa?aa I.A., Iaeueiee O.I., THoeiaiei E.?., Nieieaiei A.E. A?iiene/ia
ei?aeoe?y a?aeaeaeaiiai aieeao ?ii?coth/iai aei?ii?iaiiy ia ooieoe??
?ioiii? oa oe?ai?aeii? nenoaie // Iaoa?. X?V c’?caeo Oe?a?inueeiai
o?c?ieia?/iiai oiaa?enoaa, Ee?a, 1994 ?. — N.131-132.

8. Nieieaiei A.E. Aeeiai?ea ni?aa?aeiioaiiy CD4+/CD8+ o in?a, ui caciaee
o?eaaeiai aieeao iaeeo aeic ?ii?coth/iai ii?ii?iaiiy// I?aoe? eiio.
“Iniaeeaino? oi?ioaaiiy oa noaiiaeaiiy ineoio?c?ieia?/ieo ooieoe?e a
iioiaaiac?” — Ee?a-*a?eane — 1995. — N.83.

9. Nieieaiei A.E. Ii?ooaiiy ?ioii?aaoeyoi?iiai ?iaeaeno o in?a, ui
i?iaeeaathoue ia ?aae?aoe?eii caa?oaeiaieo oa?eoi??yo // I?aoe? i?aeia?.
iaoeiai-i?aeo. eiio. “ *i?iiaeeue: aeieia?y, i?e?iaea oa noni?euenoai” —
Oiaiue -1996.-N.261.

10. Ai?/ei O.O., Aa?aa I.A., Ai?/ei E.I., Nieieaiei A.E., Iaeueiee N.A.
Ooieoe?? ?ioiii? nenoaie o nooaeaio?a oaeoeueoaoo o?ce/ii? eoeueoo?e
*a?eanueeiai aea?aeoi?aa?neoaoo // I?aoe? i?aeia?. iaoeiai-i?aeo. eiio.
“O?ce/ia eoeueoo?a, nii?o oa caei?ia’y”. – *a?eane —
Ia?ayneaa-Oiaeueieoeueeee, 1996. — N.5.

11. Ai?/ei O.O., Aa?aa I.A., Ai?/ei E.I., Nieieaiei A.E., Iaeueiee N.A.
Aieea aeaaeai?/iiai no?ano ia ooieoe?? ?ioiii? nenoaie o nooaeaio?a
oaeoeueoaoo o?ce/ii? eoeueoo?e // I?aoe? i?aeia?. iaoeiai-i?aeo. eiio.
“Aaeaioaoe?ei? iiaeeeaino? ae?oae ? iieiae?” — Iaeana, 1996. — N. 11.

12. Boyechko F.F., Bayeva E.V., Socolenko V.L., Melnik S.G. Effects of
low doses ionizing radiation on the cellular immunity // Radiology 1997,
Immaging, Science & Oncology, Birminham, UK – 1997. — P. 23.

13. Aa?aa I.A., Nieieaiei A.E. Aieea ineoiaiioe?eiiai iaaaioaaeaiiy ia
aeaye? iieacieee ?ioiii? nenoaie nooaeaio?a // I?aoe? eiio.
“?iaeea?aeoaeuei? ineoio?c. aeanoeaino? ethaeeie oa i?ioan?eia
ae?yeuei?noue” — Ee?a-*a?eane — 1997. -N. 11.

14. Iaeueiee O.I., Nieieaiei A.E. Aieea ii?iiaa?e/ii? a?iien?? ia aeaye?
iieacieee ea?ae?i?ani??aoi?ii? oa ?ioiii? nenoai // Iaoa??aee XV c’?caeo
Oe?a?inueeiai o?c?c?ieia?/iiai oiaa?enoaa (Aeiiaoeuee, 12-15 o?aaiy 1998
?.) — O?c?ieia?/iee aeo?iae -1998. — o.44. — N3. — C.142-143.

AIIOAOe?ss

Nieieaiei A.E. Aeni?an?y O -ee?oeiieo iiaa?oiaaeo ia?ea??a e?ioioeeoaie
o i?aeoe/ii caei?iaeo in?a, ui caciaee aieeao oaeoi??a aaa??? ia *AAN. —
?oeiien.

Aeena?oaoe?y ia caeiaoooy iaoeiaiai nooiaiy eaiaeeaeaoa a?ieia?/ieo iaoe
ca niaoe?aeuei?noth 03.00.13 — o?c?ieia?y ethaeeie ? oaa?ei. — ?inoeooo
o?c?ieia?? ?i. I.I. Aiaiiieueoey IAI Oe?a?ie, Ee?a, 1998.

Aeena?oaoe?th i?enay/aii ieoaiiyi noaio ee?oeiiiai ?ioi?oaoo ianaeaiiy
Oe?a?ie, ui caciaei ae?? oaeoi??a aaa??? ia *i?iiaeeuenuee?e AAN, /a?ac
7-10 ?ie?a i?ney eaoano?ioe. O aeena?oaoe?? aeei?enoaii
?ioiioeoi?anoeaioiee iaoiae aeine?aeaeaiiy aeni?an?? O-ee?oeiieo
iiaa?oiaaeo ia?ea??a. Anoaiiaeaii, ui a in?a, ui caciaee ye aino?i?, oae
? o?ii?/ii? ae?? iaeeo aeic ?ii?coth/i? ?aae?aoe??, niinoa??aa?oueny
iiaeeo?eaoe?y, ii??aiyii c eiio?ieai, aeni?an?? iiaa?oiaaeo aioeaai?a
O-e?ioioeeo?a. Oea i?iyaey?oueny o cieaeaii? i?ioeaioiiai ai?noo c??eeo
CD3+ -, CD5+ -O-ee?oei, ?ioii?aaoeyoi?iiai ?iaeaeno CD4+/CD8+, i?ioeaioo
iaoo?aeueieo e?ea?ieo ee?oei c oaiioeiii CD3-16+56+ oa i?aeaeuaii?
i?ioeaioiiai ai?noo e?ioioeeo?a c oaiioeiaie CD4+CD25+ oa CD4+HLA-DR+.
Aeyaeaii ei?aeoe?th iieaciee?a ee?oeiiiai ?ioi?oaoo o iaoeaioe?a
oa?eoi??e iineeaiiai ?aae?iaeieia?/iiai eiio?ieth i?ney naain?a
ii?iiaa?e/ii? a?iien?? ? i?ia?aei-, iie?a?oai?iioa?ai??. Iniiai?
?acoeueoaoe i?aoe? iiaeooue neoaeeoe oai?aoe/iith iniiaith aeey ?ic?iaee
iaoiae?a ?ioiiei?aeoe?? o ianaeaiiy, ui caciaei ae?? oaeoi??a aaa??? ia
*AAN.

Eeth/ia? neiaa: aeni?an?y CD3, CD5, CD4, CD8, CD16, ND56, CD25, HLA-DR
-O-ee?oeiieo aioeaai?a, oaeoi?e aaa??? ia *AAN, ?ii?coth/a ii?ii?iaiiy,
ii?iiaa?e/ia a?iien?y, i?ia?aei-, iie?a?oai?iioa?ai?y.

AIIIOAOeEss

Nieieaiei A.E. Yeni?anney O-eeaoi/iuo iiaa?oiinoiuo ia?ea?ia
eeioioeeoaie o i?aeoe/anee caei?iauo eeoe, iiaeaa?aoeony aeeyieth
oaeoi?ia aaa?ee ia *AYN. — ?oeiienue.

Aeenna?oaoeey ia nieneaiea o/aiie noaiaie eaiaeeaeaoa aeieiae/aneeo iaoe
ii niaoeeaeueiinoe 03.00.13 — oeceieiaey /aeiaaea e aeeaioiuo. —
Einoeooo oeceieiaee ei. A.A. Aiaiiieueoea IAI Oe?aeiu, Eeaa, 1998.

Aeenna?oaoeey iinayuaia aii?inai ninoiyiey eeaoi/iiai eiioieoaoa
ianaeaiey Oe?aeiu, iiaeaa?aoaainy aicaeaenoaeth oaeoi?ia aaa?ee ia
*a?iiaueueneie AYN, /a?ac 7-10 eao iinea eaoano?iou. A aeenna?oaoeee
eniieueciaai eiioiioeoi?anoeaioiue iaoiae enneaaeiaaiey yeni?annee O
-eeaoi/iuo iiaa?oiinoiuo ia?ea?ia. Onoaiiaeaii, /oi o eeoe,
iiaeaa?aoeony eae ino?iio, oae e o?iie/aneiio aicaeaenoaeth iaeuo aeic
eiiece?othuae ?aaeeaoeee, iaaethaeaaony iiaeaeeoeeaoeey, n?aaieoaeueii n
eiio?ieai, yeni?annee iiaa?oiinoiuo aioeaaiia O-eeioioeeoia. Yoi
i?iyaeyaony a nieaeaiee i?ioeaioiiai niaea?aeaiey c?aeuo CD3+ -, CD5+
-O-eeaoie, eiioii-?aaoeyoi?iiai eiaeaena CD4+/CD8+, i?ioeaioa
iaoo?aeueiuo eeeea?iuo eeaoie n oaiioeiii ND3-16+56+ e oaaee/aiee
i?ioeaioiiai niaea?aeaiey eeioioeeoia c oaiioeiaie CD4+CD25+ e
CD4+HLA-DR+. Auyaeaii ei??aeoeeth iieacaoaeae eeaoi/iiai eiioieoaoa o
aeeoaeae oa??eoi?ee oneeaiiiai ?aaeeiyeieiae/aneiai eiio?iey iinea
naainia ii?iiaa?e/aneie aeiienee e ieia?aei-, iiee-aeoaieiioa?aiee.
Aeaaiua ?acoeueoaou ?aaiou iiaoo neoaeeoue oai?aoe/aneei iniiaaieai aeey
?ac?aaioee iaoiaeia eiioiiei??aeoeee o ianaeaiey, iiaeaa?aoaainy
aicaeaenoaeth oaeoi?ia aaa?ee ia *AYN.

Eeth/aaua neiaa: yeni?anney CD3, CD5, CD4, CD8, CD16, CD56, CD25, HLA-DR
-O-eeaoi/iuo aioeaaiia, oaeoi?u aaa?ee ia *AYN, eiiece?othuaa iaeo/aiea,
ii?iiaa?e/aneay aeiieney, ieia?aei-, iieeaeoaieii-oa?aiey.

ANNOTATION

Sokolenko V.L. T cells surface markers expression of lymphocytes of
people, injured by effect of accident factors of CAS. Manuscript.

Thesis for a candidates degree of biological sciences by speciality
03.00.13 — Physiology of a human being and animals. — The Institute of
Physiology of Academy of Sciences of Ukraine, named after O.O.
Bogomolets, Kyiv, 1998.

The dissertation deals with research of cellular immunity state of
people injured by the effect of atomic accident in Chornobyl in 7-10
years later. The immunofluorescent method analysis of T cells surface
markers expression was used. Data obtained show that there was revealed
T cells surface antygen modification of people, injured in acute and
chronical exposure by low doses of the ionizing radiation comparatively
with control. Such state are manifested in rated decrease of CD3+ and
CD5+ mature T cells, immuno-regulating index (CD4+/CD8+ ratio),
CD3-16+56+ natural killer cells and rated increase cells with CD4+CD25+
and CD4+HLA-DR+ phenotype. The revealed changes correction by means of
normobaric hypoxia and mineral-, polyvitaminotherapy seances were
observed. The results of the work obtained may be of theoretical basis
for immunocorrection of people injured to effect by accident factors of
CAS.

Key words: CD3, CD5, CD4, CD8, CD16, CD56, CD25, HLA-DR T cells antigens
expression, factors of CAS accident, ionizing radiation, normobaric
hypoxie, mineral-, polyvitaminotherapy.

Похожие записи